Clinical data | |
---|---|
Other names | PNU 156765 |
Routes of administration | Oral |
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C28H35F3N2O2 |
Molar mass | 488.595 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
FCE 28260 is an azasteroidal 5α-reductase inhibitor which was developed for the treatment of benign prostatic hyperplasia and androgenic alopecia (pattern hair loss) in the 1990s but was never marketed. FCE 28260 has been found to inhibit rat and human 5α-reductase with half-maximal inhibitory concentrations (IC50) of 15 and 16 nM, respectively, while finasteride had values of 30 and 52 nM.
References
- ^ Giudici D, Briatico G, Cominato C, Zaccheo T, Iehlè C, Nesi M, et al. (June 1996). "FCE 28260, a new 5 alpha-reductase inhibitor: in vitro and in vivo effects". The Journal of Steroid Biochemistry and Molecular Biology. 58 (3): 299–305. doi:10.1016/0960-0760(96)00040-4. PMID 8836165. S2CID 140209512.
- EP 0782582, di Salle E, Nesi M, Panzeri A, "Epimers of (22RS)-N-(1,1,1-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide", published 1997-07-09
- "FCE 28260". AdisInsight. Springer Nature Switzerland AG.
This drug article relating to the genito-urinary system is a stub. You can help Misplaced Pages by expanding it. |